Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease

References

• Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606–1615.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3:505–521.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dialysis Transplant. 2002;17:33–40.
   PubMed Web of Science ®Google Scholar
• Raj DS, Carrero JJ, Shah VO, et al. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis. 2009;54:1072–1080.
   PubMed Web of Science ®Google Scholar
• Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002;13:28–36.
   PubMed Web of Science ®Google Scholar
• Meuwese CL, Halbesma N, Stenvinkel P, et al. Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. Nephrol Dial Transplant. 2010;25:3717–3723.
   PubMed Web of Science ®Google Scholar
• Boehme M, Kaehne F, Kuehne A, Bernhard W, Schroder M, Pommer W, et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007;22:2224–29.
   PubMed Web of Science ®Google Scholar
• Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Heimburger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dialysis Transplant. 2000;15:953–960.
   PubMed Web of Science ®Google Scholar
• Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001;44:2841–2850.
   PubMed Web of Science ®Google Scholar
• Boehme M, Kaehne F, Kuehne A, et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007;22:2224–2229.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Nguyen-Khoa T, Jungers P, et al. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant. 1999;14:76–78.
   PubMed Web of Science ®Google Scholar
• Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999;56:1078–1083.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
   PubMed Web of Science ®Google Scholar
• Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. 1996;239:70–76.
   PubMed Web of Science ®Google Scholar
• Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis. Lancet. 1987;329:628–629.
   Google Scholar
• Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636–641.
   PubMed Web of Science ®Google Scholar
• Korevaar JC, Van manen JG, Dekker FW, Waart DR, Elisabeth W. Boeschoten EW, et al. Effect of an increase in c-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004;15:2916–22.
   PubMed Web of Science ®Google Scholar
• Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2:889–897.
   PubMed Web of Science ®Google Scholar
• Malaponte G, Libra M, Bevelacqua Y, et al. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines. Int J Mol Med. 2007;20:471–481.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Stenvinkel P, Qureshi AR, et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol. 2009;22:774–782.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997;272:32817–32823.
   PubMed Web of Science ®Google Scholar
• Hacişevki A. Effect of haemodialysis on oxidative stress in patients with chronic renal failure. J Fac Pharm Ankara. 2008;37:91–100.
   Google Scholar
• Ramakrishna P, Reddy EP, Suchitra MM, et al. Effect of reuse of polysulfone membrane on oxidative stress during haemodialysis. Indian J Nephrol. 2012;22:200–205.
   PubMedGoogle Scholar
• Reddy PE, Suchitra MM, Reddy SV, et al. Ferric reducing ability of plasma and lipid peroxidation in haemodialysis patients: intradialytic changes. Int J Nephrol Urol. 2010;2:414–421.
   Google Scholar
• Ansarihadipour H, Dorostkar H. Comparison of plasma oxidative biomarkers and conformational modifications of hemoglobin in patients with diabetes on hemodialysis. Iran Red Crescent Med J. 2014;16:e22045.
   PubMed Web of Science ®Google Scholar
• Reddy PE, Suchitra MM, Bitla AR, et al. Antioxidant enzymes status in South Indian haemodialysis patients. Int J Biol Med Res. 2011;2:682–687.
   Google Scholar
• Gerardi G, Usberti M, Martini G, et al. Plasma total anti-oxidant capacity in hemodialyzed patients and its relationships to other biomarkers of oxidative stress and lipid peroxidation. Clin Chem Lab Med. 2002;40:104–110.
   PubMed Web of Science ®Google Scholar